Patents Issued in November 24, 2020
  • Thiazolyl-containing compounds for treating proliferative diseases
    Patent number: 10844077
    Abstract: The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g. Src family kinases (e.g. hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g. myelodysplasia, leukemia, lymphoma, (e.g. Waldenström's macroglobulinemia)) and in inducing apoptosis in a cell (e.g. malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Sara Jean Buhrlage, Steven P. Treon, Hwan Geun Choi, Yuan Xiong, Guang Yang
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 10844078
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: November 24, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
  • Spiro aromatic ring compound and application thereof
    Patent number: 10844079
    Abstract: Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 24, 2020
    Assignee: Etern Biopharma (Shanghai) Co., Ltd.
    Inventors: Qiangang Zheng, Ming Xu, Qinglong Zeng, Jing Li, Hao Zhuge
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10844080
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: November 24, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Protected organoboronic acids with tunable reactivity, and methods of use thereof
    Patent number: 10844081
    Abstract: Disclosed are a range of protected organoboronic acid reagents useful in the modular assembly of complex organic compounds. The reactivities of the protected organoboronic acid reagents may be varied predictably by changes to the number and identities of their substituents. Also disclosed are methods of using the protected organoboronic acid reagents in the synthesis of organic compounds.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 24, 2020
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Michael Schmidt, Greg Morehouse, Robert W. Pipal
  • Methods of making metal halide perovskites
    Patent number: 10844083
    Abstract: Provided herein are methods of making metal halide perovskites, including methods of making bulk crystals or micro crystals. The metal halide perovskites may be a light emitting material.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: November 24, 2020
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Biwu Ma, Chenkun Zhou, Zhao Yuan
  • Organic electroluminescent materials and devices
    Patent number: 10844084
    Abstract: A compound including a first ligand LA having the formula: is disclosed.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 24, 2020
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Zhiqiang Ji, Lichang Zeng
  • Organic electroluminescent materials and devices
    Patent number: 10844085
    Abstract: A compound having the formula [LA]3-nIr[LB]n is disclosed. In the formula, LA is and LB is Formula I.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: November 24, 2020
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Zhiqiang Ji, Jui-Yi Tsai, Lichang Zeng, Alexey Borisovich Dyatkin, Walter Yeager, Eric Margulies, Pierre-Luc T. Boudreault
  • Method for producing halogen-crosslinked iridium dimer
    Patent number: 10844086
    Abstract: A method for producing a halogen-crosslinked iridium dimer with increased purity that is used as a precursor in production of a cyclometalated iridium complex useful as a phosphorescent material for organic electroluminescent devices, organic electrochemiluminescent devices, luminescent sensors, photosensitizing pigments, photocatalysts, luminescent probes, various light sources, and the like. The halogen-crosslinked iridium dimer is represented by the following formula: In this formula, each X represents a halogen atom, each CyA represents an optionally substituted five- or six-membered cyclic ring containing nitrogen atoms, and is linked to iridium via the nitrogen atoms, and each CyB represents an optionally substituted five- or six-membered ring containing carbon atoms, and is linked to iridium via the carbon atoms. CyA and CyB can be linked together to form an optionally substituted ring.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 24, 2020
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hideo Konno, Junichi Taniuchi, Rumi Kobayashi, Yasushi Masahiro
  • Method of suppressing formation of photocrosslink, and photoreactive nucleic acid in which auto-crosslink formation is suppressed
    Patent number: 10844087
    Abstract: Provided is a means for preventing the inactivation of a photoresponsive nucleic acid probe by suppressing the formation of a photocrosslink between a modified nucleotide having a structure corresponding to the monomer of Formula (II) or an amino acid analogue of a nucleotide having a structure corresponding to the monomer of Formula (III) and a modified nucleotide having a structure corresponding to the monomer of Formula (I), wherein the modified nucleotide replaces at least one constituent nucleotide which is the photocrosslinkable 1-thyminyl or 1-uracilyl, by substituting at least one constituent nucleotide which is the photocrosslinkable 1-thyminyl or 1-uracilyl with a modified nucleotide having a structure corresponding to the monomer of Formula (I).
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 24, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Kenzo Fujimoto, Shigetaka Nakamura
  • Process for the preparation of estetrol
    Patent number: 10844088
    Abstract: The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3, 15a, 16a, 17?-tetraol (estetr-01), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10), 16-tetraene, wherein A is a protecting group and B is —Si(R2)3. The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10), 15-tetraen-17-one, in which A is a protecting group, via silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, and B is —Si(R2)3.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: November 24, 2020
    Assignee: ESTETRA SPRL
    Inventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink, Franciscus Wilhelmus Petrus Damen, Michiel Christian Alexander Van Vliet
  • Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
    Patent number: 10844089
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 24, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Shunlin Ren, William M. Pandak
  • Hemiasterlin derivatives for conjugation and therapy
    Patent number: 10844090
    Abstract: Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 24, 2020
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Toni Kline, Qun Yin, Krishna Bajjuri
  • Peptide with antidepressant activity and therapeutic effect against Alzheimer's disease
    Patent number: 10844091
    Abstract: The invention includes a tetrapeptide to be used in the treatment of Alzheimer's disease and depression. The tetrapeptide comprises the general formula, acetyl-X-ARG-ARG-amide, where X=-(D-ARG)-ARG-; -(D-LYS)-LYS-; or -(D-MET)-MET-. On the basis of the combination of pharmacological properties identified, a preparation including the tetrapeptide has potential for clinical use as a nootropic, neuroprotective, and antidepressant agent.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 24, 2020
    Assignee: “VERTA RESEARCH-PRODUCTION COMPANY”LTD
    Inventors: Roman Danilovich Dejko, Alexandr Alexandrovich Kolobov, Elena Arturovna Kampe-Nemm, Vladimir Michajlovich Shpen
  • Peptide for promoting regeneration of dentin or dental pulp tissue
    Patent number: 10844092
    Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 24, 2020
    Assignee: HysensBio Co., Ltd.
    Inventors: Joohwang Park, Jihyun Lee
  • Peptide compounds to regulate the complement system
    Patent number: 10844093
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: November 24, 2020
    Assignee: REALTA HOLDINGS, LLC
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Biosynthetic proline/alanine random coil polypeptides and their uses
    Patent number: 10844094
    Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) fconstituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 24, 2020
    Assignees: TECHNISCHE UNIVERSITÄT MÜNCHEN, XL-PROTEIN GMBH
    Inventors: Arne Skerra, Uli Binder, Martin Schlapschy
  • Recombinant viral vectors
    Patent number: 10844095
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: November 24, 2020
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
  • Therapeutic HPV18 vaccines
    Patent number: 10844096
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 24, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Evelien Margaretha Bunnik, Jerôme Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • Engineered influenza antigenic polypeptides and immunogenic compositions thereof
    Patent number: 10844097
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignee: Sanofi Pasteur Inc.
    Inventors: Tod Strugnell, Eliud Oloo
  • Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein
    Patent number: 10844098
    Abstract: The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and the Neisseria meningitidis O-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: November 24, 2020
    Assignee: Institute of Biotechnology, Academy of Military Medical Sciences, China
    Inventors: Jun Wu, Chao Pan, Peng Sun, Hengliang Wang, Bo Liu, Zhehui Peng, Li Zhu, Shaohong Chang, Xin Gong, Erling Feng, Bin Wang, Ming Zeng
  • Streptavidin muteins and methods of using them
    Patent number: 10844099
    Abstract: The invention concerns novel streptavidin muteins. In one embodiment such a mutein (a) contains two or more mutations in the region of the amino acid positions 117 to 121 with reference to the amino acid sequence of wild type streptavidin of which amino acid residues 14 to 139 are as set forth at SEQ ID NO:212 and (b) has a higher binding affinity than each of (i) a streptavidin mutein “1” (SEQ ID NO: 16) that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 24, 2020
    Assignee: IBA GMBH
    Inventor: Thomas Schmidt
  • Mutant strain of filamentous fungus and use therefor
    Patent number: 10844100
    Abstract: A filamentous fungus mutant strain showing improved secretory protein production and a method of producing a protein using the filamentous fungus are provided. The method of producing a protein comprises a step of culturing a filamentous fungus mutant strain in which a function of tubulin is reduced or lost and collecting a protein from a culture product.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: November 24, 2020
    Assignee: Kao Corporation
    Inventors: Nozomu Shibata, Wataru Ogasawara, Yosuke Shida
  • Plant-derived elastin binding protein ligands and methods of using the same
    Patent number: 10844101
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: November 24, 2020
    Assignees: Elastogenesis, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
    Patent number: 10844102
    Abstract: Peptides that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: November 24, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Method for the purification of G-CSF
    Patent number: 10844103
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 24, 2020
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • Modified interleukin-7 protein
    Patent number: 10844104
    Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 24, 2020
    Assignee: GENEXINE, INC.
    Inventors: Se Hwan Yang, Donghoon Choi, Hye Seong Lim
  • De novo design of potent and selective interleukin mimetics
    Patent number: 10844105
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 24, 2020
    Assignees: University of Washington, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
  • Fusion proteins comprising an engineered knottin peptide and uses thereof
    Patent number: 10844106
    Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 24, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
  • HIV VPR-specific T-cell receptors
    Patent number: 10844107
    Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: November 24, 2020
    Assignee: ALTOR BIOSCIENCE, LLC
    Inventors: Marilyn Fernandez, Bai Liu, Warren Marcus, Hing C. Wong
  • Single-chain CD27-receptor agonist proteins
    Patent number: 10844108
    Abstract: Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Method for producing erythrocyte proteins
    Patent number: 10844109
    Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 24, 2020
    Assignees: Institut National Transfusion Sanguine, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7
    Inventors: Isabelle Mouro-Chanteloup, Sandrine Genetet
  • O-linked glycoforms of polypeptides and method to manufacture them
    Patent number: 10844110
    Abstract: The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: November 24, 2020
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Niels Kristian Klausen, Daniel E. Rasmussen
  • Prostate specific membrane antigen binding fibronectin type III domains
    Patent number: 10844111
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • Method for purifying antibody or antibody fragment containing ?-chain variable region
    Patent number: 10844112
    Abstract: A method for purifying an antibody or an antibody fragment containing ?-chain variable region includes adsorbing at least one of the antibody or the antibody fragment onto an affinity separation matrix by contacting a liquid sample with the affinity separation matrix, washing the affinity separation matrix to remove impurities, and separating the at least one of the antibody or the antibody fragment from the affinity separation matrix by using an acetate buffer. The liquid sample includes the at least one of the antibody or the antibody fragment. The affinity separation matrix includes a water-insoluble carrier and a ligand selected from the group consisting of Protein L, a variant of Protein L, a domain of Protein L, and a variant of the domain. The ligand is immobilized on the water-insoluble carrier.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: November 24, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Dai Murata, Shinichi Yoshida, Kazunobu Minakuchi
  • Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
    Patent number: 10844113
    Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 24, 2020
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and Research
    Inventors: Zenjiro Sampei, Xing'er Christine Koo, Katja Fink, Roland Zuest
  • Anti-Psl binding molecules and uses thereof
    Patent number: 10844114
    Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: November 24, 2020
    Assignee: MedImmune Limited
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Bone-targeting antibodies
    Patent number: 10844115
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
    Patent number: 10844116
    Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 24, 2020
    Assignees: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, H. LUNDBECK A/S
    Inventors: Adisa Kuburas, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren, Bianca Mason, Levi P. Sowers, Andrew F. Russo, Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix
  • Human alpha-folate receptor chimeric antigen receptor
    Patent number: 10844117
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 24, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Treatment of inflammatory skin disease
    Patent number: 10844118
    Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: November 24, 2020
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian E. Winau, Ji Hyung Kim
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 10844119
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 24, 2020
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Humanized antigen-binding domains and methods of use
    Patent number: 10844120
    Abstract: The invention provides a humanized anti-CD19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 24, 2020
    Assignee: Kite Pharma, Inc.
    Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
  • Antibodies binding LAG-3 and uses thereof
    Patent number: 10844121
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds LAG-3. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-LAG-3 antibody of the invention.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 24, 2020
    Assignee: NANJING LEADS BIOLABS CO., LTD
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Lijun Zhou
  • Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
    Patent number: 10844122
    Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 10844123
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Therapeutic CD47 antibodies
    Patent number: 10844124
    Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 24, 2020
    Assignee: Arch Oncology, Inc.
    Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
  • Anti-inflammatory polypeptides
    Patent number: 10844125
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: November 24, 2020
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1
    Patent number: 10844126
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Antibodies that bind EGFR and ErbB3
    Patent number: 10844127
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 24, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers